Trofinetide: complete guide

Trofinetide is a synthetic tripeptide approved by FDA as Daybue in 2023, the first treatment for Rett syndrome. This guide covers its structure, labeled use, trials and warnings.

Complete guide5 min read

Key takeaway

FDA approved trofinetide as Daybue on March 10, 2023. It has a molecular weight of 315.32 g/mol, small even for a peptide. In the LAVENDER trial, diarrhea occurred in 82% of treated patients versus 20% on placebo, per the label, while both co-primary scores favored trofinetide.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Daybue on March 10, 2023.” (this article)
ClassNeuropeptides
Body systemsBrain & nervous system
Studies cited3 in this article · 3 across 1 article on Trofinetide
Related productsNeuropeptides

Trofinetide is a synthetic tripeptide, a chain of just three amino acids, modeled on a fragment of the growth factor IGF-1. FDA approved it as the first treatment for Rett syndrome. This guide covers its structure, what is known about how it works, its labeled use, trials and label warnings. Sources were checked on November 17, 2026.

Quick answer: Trofinetide is a prescription tripeptide sold as Daybue. Its label covers Rett syndrome in adults and children 2 years and older. The label says its mechanism in Rett syndrome is unknown. It has no boxed warning, but diarrhea, weight loss and vomiting are label warnings.

Vitrapep does not sell trofinetide; this page is a reference summary of published research and regulatory information.

What is trofinetide?

ChEBI text, quoted in PubChem, describes trofinetide as “a tripeptide comprising of glycine, 2-methyl-L-proline, and L-glutamic acid” (PubChem CID 11318905). The 2-methyl group on proline is a small chemical change to a natural amino acid. PubChem lists the formula as C13H21N3O6 and the molecular weight as 315.32 g/mol.

It counts as a peptide because its three amino acids are joined by peptide bonds. The LAVENDER report calls it a synthetic analog of the first three amino acids of IGF-1, insulin-like growth factor 1 (Neul et al., 2023). Our peptide primer and peptide bond explainer cover the basics.

Drugs@FDA lists the original approval of Daybue (NDA 217026) on March 10, 2023, to Acadia Pharmaceuticals (Drugs@FDA). FDA announced it as the first treatment for Rett syndrome (FDA, 2023). The current label also covers a second product, Daybue Stix.

Table 1

Trofinetide: key facts

Fact Detail
Structure type Synthetic tripeptide (glycine, 2-methyl-L-proline, L-glutamic acid)
Class Synthetic analog of an IGF-1 fragment; Rett syndrome treatment
Molecular formula C13H21N3O6
Molecular weight 315.32 g/mol
First FDA approval March 10, 2023 (Daybue, NDA 217026)
Brand names (US) Daybue, Daybue Stix

How does trofinetide work?

The honest answer is that no one knows for sure. The Daybue label states: “The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown” (Daybue label, 2026).

What is known is its origin. IGF-1 is a growth factor protein, and trofinetide is modeled on its first three amino acids. Its proline carries an extra methyl group, unlike the natural fragment. For the full-length growth factor, see our mecasermin (recombinant IGF-1) guide. Claims about specific brain pathways go beyond what the label states, so we do not repeat them here.

What is trofinetide approved for?

The Daybue label covers “the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.” It lists no contraindications.

FDA describes Rett syndrome as “a rare, genetic neurological and developmental disorder that affects the way the brain develops.” FDA adds that it primarily affects females, at about 1 in 10,000, and more rarely affects males. FDA’s list of novel drug approvals for 2023 includes Daybue (FDA, 2023 list).

What did the key trials show?

LAVENDER. This was a 12-week, randomized, double-blind, placebo-controlled phase 3 human trial (NCT04181723). It enrolled 187 girls and women aged 5 to 20 with Rett syndrome: 93 on trofinetide and 94 on placebo. There were two co-primary end points.

  • Rett Syndrome Behaviour Questionnaire (caregiver-rated): least-squares mean difference −3.2 (95% CI, −5.7 to −0.6; p=0.018).
  • Clinical Global Impression-Improvement (clinician-rated): difference −0.3 (95% CI, −0.5 to −0.1; p=0.003).

Lower scores mean improvement on both scales. The published report gives effect sizes of 0.37 and 0.47. It also reports a benefit on a communication measure, the key secondary end point (P=0.0064) (Neul et al., 2023).

LILAC. This 40-week open-label extension treated 154 LAVENDER participants. Behaviour questionnaire scores improved by about 7 points from the original baseline in both former groups. Diarrhea (74.7%) and vomiting (28.6%) were the most common adverse events, and diarrhea led 21.4% to withdraw (Percy et al., 2024).

DAFFODIL. This small open-label study treated 15 girls aged 2 to 4. Diarrhea (80.0%) and vomiting (53.3%) were the most common events, mostly mild or moderate (Percy et al., 2025). Neither extension had a placebo group.

What side effects does the label list?

The Daybue label has no boxed warning. It lists diarrhea and vomiting as the most common adverse reactions, in at least 10% of patients and at least 2% more than placebo. In LAVENDER, the label reports:

  • Diarrhea: 82% with trofinetide and 20% with placebo.
  • Vomiting: 29% and 12%.
  • Fever: 9% and 4%; seizure: 9% and 6%; decreased appetite: 8% and 2%.

The label’s three warnings are diarrhea, weight loss and vomiting. It states that “12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline,” compared with 4% on placebo. In the trial, 19% of trofinetide patients withdrew because of adverse reactions, most often diarrhea (15%).

What is trofinetide’s regulatory status, and how is it used in research?

Trofinetide is a prescription drug in the United States, marketed by Acadia Pharmaceuticals as Daybue and Daybue Stix. The current label was revised in March 2026.

The research summarized here is clinical: a randomized human trial and two open-label studies in Rett syndrome. We found no documented role for trofinetide as a laboratory reagent in the sources we checked.

Frequently asked questions about trofinetide

Is trofinetide a peptide?

Yes. It is a tripeptide: glycine, 2-methyl-L-proline and L-glutamic acid joined by peptide bonds.

When was trofinetide approved?

Drugs@FDA lists the original approval of Daybue on March 10, 2023.

Is trofinetide related to IGF-1?

It is a synthetic analog of the first three amino acids of IGF-1, per the LAVENDER report. It is not IGF-1 itself.

How does trofinetide work in Rett syndrome?

The label says the mechanism is unknown.

What are the main side effects?

Diarrhea and vomiting are the most common. The label also warns about weight loss. There is no boxed warning.

What to know now

  • Structure: synthetic tripeptide modeled on an IGF-1 fragment; 315.32 g/mol.
  • Approval: Daybue, March 10, 2023, the first FDA-approved treatment for Rett syndrome.
  • Mechanism: unknown in Rett syndrome, per the label.
  • Evidence: LAVENDER met both co-primary end points in 187 girls and women.
  • Label: Rett syndrome in adults and children 2 years and older.
  • Safety: no boxed warning; diarrhea in 82% vs 20% on placebo; weight loss and vomiting warnings.

What we’re watching

Further revisions to the Daybue label on DailyMed, last revised in March 2026. Related guides: mecasermin and ziconotide.

More for brain & nervous system

All 12 compounds for brain & nervous system

Sources: ACADIA Pharmaceuticals Inc 2026, DAYBUE and DAYBUE STIX (trofinetide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 217026 (DAYBUE) . Retrieved November 17, Drugs@FDA: NDA 217026 (DAYBUE); National Center for Biotechnology Information 2026, PubChem compound summary for CID 11318905, trofinetide; U.S. Food and Drug Administration 2023, FDA approves first treatment for Rett syndrome; U.S. Food and Drug Administration 2026, Novel drug approvals for 2023; Neul 2023, Nature Medicine, 29; ACADIA Pharmaceuticals Inc 2019, Study of trofinetide for the treatment of girls and women with Rett syndrome; Percy 2024, Med, 5; Percy 2025, Med, 6. All 9 citations

Back to the research library

References

  1. ACADIA Pharmaceuticals Inc. (2026). DAYBUE and DAYBUE STIX (trofinetide) prescribing information (revised 3/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67e6f2d9-21f6-466f-9def-826c6a4b8257
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 217026 (DAYBUE). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217026
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 11318905, trofinetide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/11318905
  4. U.S. Food and Drug Administration. (2023). FDA approves first treatment for Rett syndrome. Retrieved November 17, 2026, from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-rett-syndrome
  5. U.S. Food and Drug Administration. (2026). Novel drug approvals for 2023. Retrieved November 17, 2026, from https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
  6. Neul, J. L., et al. (2023). Trofinetide for the treatment of Rett syndrome: A randomized phase 3 study. Nature Medicine, 29(6), 1468–1475. https://doi.org/10.1038/s41591-023-02398-1
  7. ACADIA Pharmaceuticals Inc. (2019). Study of trofinetide for the treatment of girls and women with Rett syndrome (LAVENDER; ClinicalTrials.gov ID NCT04181723). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04181723
  8. Percy, A. K., et al. (2024). Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study. Med, 5(9), 1178–1189.e3. https://doi.org/10.1016/j.medj.2024.05.018
  9. Percy, A. K., et al. (2025). Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome. Med, 6(6), 100608. https://doi.org/10.1016/j.medj.2025.100608